Patents by Inventor David Mu

David Mu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7462465
    Abstract: The present invention provides nucleic acid and protein sequences for a novel potassium channel protein, KCNB. The herein-disclosed sequences can be used for any of a number of purposes, including for the specific detection of KCNB, for the identification of molecules that associate with and/or modulate the activity of KCNB, to diagnose any of a number of conditions associated with KCNB or KCNB activity, or to modulate the number or activity of KCNB molecules in a mammal.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: December 9, 2008
    Assignee: Amgen, Inc.
    Inventors: David Mu, Scott Powers
  • Publication number: 20080234470
    Abstract: The present invention provides nucleic acid and protein sequences for a novel potassium channel protein, KCNB. The herein-disclosed sequences can be used for any of a number of purposes, including for the specific detection of KCNB, for the identification of molecules that associate with and/or modulate the activity of KCNB, to diagnose any of a number of conditions associated with KCNB or KCNB activity, or to modulate the number or activity of KCNB molecules in a mammal.
    Type: Application
    Filed: January 3, 2008
    Publication date: September 25, 2008
    Applicant: AMGEN INC.
    Inventors: David Mu, Scott Powers
  • Patent number: 7115368
    Abstract: The present invention provides methods, reagents, and kits for diagnosing and treating cancer in a mammal, e.g., a human. This invention is based upon the discovery that Pellino 1 or 2 is overexpressed and/or amplified in cancer. Methods to detect cancer or a propensity to develop cancer, to monitor the efficacy of a cancer treatment, and to treat cancer, by inhibiting the expression and/or activity of Pellino 1 or 2 in a cancer cell are included.
    Type: Grant
    Filed: December 28, 2001
    Date of Patent: October 3, 2006
    Assignee: Amgen SF, LLC
    Inventors: Scott Powers, David Mu, Phil Xiang, Yue Peng
  • Publication number: 20050026194
    Abstract: There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing a gene, which is amplified in many types of cancer. The amplified genes, their expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or as vaccines; they also are used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.
    Type: Application
    Filed: June 15, 2004
    Publication date: February 3, 2005
    Applicant: Tularik Inc.
    Inventor: David Mu
  • Publication number: 20040005615
    Abstract: There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the RecQL5, CTXL, USP13, MCL1, and Pellino1 genes, which are amplified in many types of cancer. The RecQL5, CTXL, USP13, MCL1, and Pellino1 genes, their expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or as vaccines; they also are used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.
    Type: Application
    Filed: May 22, 2003
    Publication date: January 8, 2004
    Inventors: Jing Li, David Mu, Jianxin Yang
  • Publication number: 20030092042
    Abstract: There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals such as humans, utilizing the Galanin, Galanin Receptor 2 (GALR2) and Galanin Receptor 3 (GALR3) genes, which are amplified in breast and/or lung and/or brain and/or colon and/or prostate and/or ovarian cancer genes. The Galanin, GALR2 and GALR3 genes and their expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or vaccine; they are also used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy. There is also disclosed a GALR2-GALR3 heterocomplex formation during tumorigenesis.
    Type: Application
    Filed: August 27, 2002
    Publication date: May 15, 2003
    Inventors: David Mu, Scott Powers
  • Publication number: 20030049645
    Abstract: There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the hepsin gene, which are amplified ovarian, and/or prostate, and/or breast, and/or lung cancer genes. The hepsin gene, its expressed protein products and antibodies are used diagnostically or as targets for cancer therapy; they are also used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.
    Type: Application
    Filed: February 12, 2002
    Publication date: March 13, 2003
    Inventors: David Mu, Scott Powers
  • Publication number: 20020150934
    Abstract: The present invention provides methods, reagents, and kits for diagnosing and treating cancer in a mammal, e.g., a human. This invention is based upon the discovery that Pellino 1 or 2 is overexpressed and/or amplified in cancer. Methods to detect cancer or a propensity to develop cancer, to monitor the efficacy of a cancer treatment, and to treat cancer, by inhibiting the expression and/or activity of Pellino 1 or 2 in a cancer cell are included.
    Type: Application
    Filed: December 28, 2001
    Publication date: October 17, 2002
    Applicant: Tularik Inc.
    Inventors: Scott Powers, David Mu, Phil Xiang, Yue Peng
  • Publication number: 20020102676
    Abstract: The present invention provides nucleic acid and protein sequences for a novel potassium channel protein, KCNB. The herein-disclosed sequences can be used for any of a number of purposes, including for the specific detection of KCNB, for the identification of molecules that associate with and/or modulate the activity of KCNB, to diagnose any of a number of conditions associated with KCNB or KCNB activity, or to modulate the number or activity of KCNB molecules in a mammal.
    Type: Application
    Filed: March 2, 2001
    Publication date: August 1, 2002
    Inventors: David Mu, Scott Powers